Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Total Assets
Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) holds total assets worth CN¥1.91 Billion CNY (≈ $279.37 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Total Assets Trend (2017–2024)
This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Also see 688117 market cap for the company's overall valuation and market capitalisation.
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Cheng Du Sheng Nuo Biotec Co. Ltd. A's total assets of CN¥1.91 Billion consist of 43.6% current assets and 56.4% non-current assets. Review Cheng Du Sheng Nuo Biotec Co. Ltd. A total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.3% |
| Accounts Receivable | CN¥133.17 Million | 8.1% |
| Inventory | CN¥304.75 Million | 18.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥52.98 Million | 3.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Cheng Du Sheng Nuo Biotec Co. Ltd. A share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cheng Du Sheng Nuo Biotec Co. Ltd. A's current assets represent 43.6% of total assets in 2024, a decrease from 46.8% in 2017.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2024, up from 10.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 6.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 18.5% of total assets.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Total Assets
Key competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
India | Rs179.65 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.46 | 1.39 | 2.32 |
| Quick Ratio | 0.90 | 0.85 | 1.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥271.28 Million | CN¥184.03 Million | CN¥191.07 Million |
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Cheng Du Sheng Nuo Biotec Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.90 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 25.2% |
| Total Assets | CN¥1.65 Billion |
| Market Capitalization | $553.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cheng Du Sheng Nuo Biotec Co. Ltd. A's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cheng Du Sheng Nuo Biotec Co. Ltd. A's assets grew by 25.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)
The table below shows the annual total assets of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.65 Billion ≈ $241.14 Million |
+25.25% |
| 2023-12-31 | CN¥1.32 Billion ≈ $192.53 Million |
+18.75% |
| 2022-12-31 | CN¥1.11 Billion ≈ $162.14 Million |
+15.83% |
| 2021-12-31 | CN¥956.62 Million ≈ $139.98 Million |
+61.32% |
| 2020-12-31 | CN¥592.98 Million ≈ $86.77 Million |
+14.27% |
| 2019-12-31 | CN¥518.92 Million ≈ $75.93 Million |
+8.50% |
| 2018-12-31 | CN¥478.25 Million ≈ $69.98 Million |
+37.35% |
| 2017-12-31 | CN¥348.20 Million ≈ $50.95 Million |
-- |
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more